Premium
Addition of tucatinib to trastuzumab and chemotherapy improves survival for patients with metastatic, HER2‐positive breast cancer
Author(s) -
Printz Carrie
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32918
Subject(s) - medicine , trastuzumab , capecitabine , metastatic breast cancer , pertuzumab , oncology , breast cancer , clinical endpoint , cancer , progression free survival , clinical trial , chemotherapy , colorectal cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom